Zydus Lifesciences Limited has informed the Exchange about press release dated 17-Oct-2022 titled 1. Zydus receives tentative approval from the USFDA for Valbenazine Capsules and 2. Zydus receives tentative approval from the USFDA for Roflumilast Tablets
Press Release Oct 17 2022
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release detailing two recent approvals from the USFDA. The approvals are for Valbenazine Capsules and Roflumilast Tablets, both intended for specific medical treatments. Valbenazine is indicated for tardive dyskinesia, while Roflumilast is for reducing COPD exacerbations. Both drugs will be manufactured at the company's facility in Ahmedabad SEZ, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Lifesciences: General updates
- Press Release Oct 06 2022
- Press Release Oct 04 2022
- Press Release Oct 03 2022
- Press Release Oct 01 2022
Later from Zydus Lifesciences
- Press Release Oct 22 2022
- Press Release Oct 26 2022
- Press Release Oct 29 2022
- Press Release Nov 03 2022
- Press Release Nov 07 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences